1 of 11 categories · Updated August 2026
SmarterDx is scored in one of the 11 categories on this site. It scores 37/50 for AI CDI and utilization review. It does not rank first in any category scored here.
Reviewed by Abishek Shahi, MD · Last reviewed August 2026
Disclosure: Abishek Shahi is Chief Medical Officer of EvidenceMD, which is scored in every category on this site by the team that publishes it. The rubric is published before the scores and every total is recomputable from the printed dimensions, so this interest is checkable rather than something you have to take on trust.
The scores
Each category has its own five-dimension rubric, so a total here is only comparable to other tools inside the same category. Every dimension is worth 10 points.
Best for pre-bill review and denial prevention
37/50
3rd of 5
| Capture accuracy | Traceability & auditability | Revenue & denial impact | EHR & deployment | Access & transparency |
|---|---|---|---|---|
| 9/10 | 8/10 | 9/10 | 8/10 | 3/10 |
Pattern
SmarterDx takes no full-mark dimension on this site. Its strongest result is 37/50 for AI CDI and utilization review.
Head to head
Only tools that share a rubric are compared. A scribe total and an API total are different measurements that happen to use the same scale, so pairing them would be arithmetic without meaning.
1 shared category · CDI
37–42EvidenceMD ahead
See the comparison1 shared category · CDI
37–34SmarterDx ahead
See the comparison1 shared category · CDI
37–36SmarterDx ahead
See the comparison1 shared category · CDI
37–38Waystar / Iodine Software ahead
See the comparisonLimits
This page aggregates scores from the category rubrics. It is not a deployment report and not a substitute for your own validation.
Scores measure documented capability, not outcomes in your clinic. SmarterDx has not been tested here against live patient data, and no score on this page reflects implementation quality, support responsiveness or contracted uptime. Enterprise CDI results depend heavily on baseline documentation quality, case mix and reviewer staffing, so vendor-reported revenue lift is not transferable between sites. Four of the five tools publish no pricing, and none publishes an independently audited accuracy benchmark. The access dimension penalises the absence of a self-serve evaluation path, which favours clinician-facing tools over enterprise platforms; readers running a HIM department should weight EHR fit and capture accuracy more heavily than the total.
Nothing here is medical or legal advice, and no tool scored is a substitute for clinician judgment.
Sourcing
Third-party assessment naming Regard, SmarterDx, Waystar/Iodine and Solventum category leaders.
Vendor documentation for concurrent CDI and chart prioritization.
Vendor documentation for combined coding and CDI workflow.
Common questions
SmarterDx is scored in one of the 11 categories on this site. It scores 37/50 for AI CDI and utilization review. It does not rank first in any category scored here. Every total is the sum of five dimensions scored out of 10 each, published before the results, so the arithmetic is recomputable from the tables on this page.
SmarterDx takes no full-mark dimension on this site. Its highest total is 37/50 for AI CDI and utilization review, ranking 3rd of 5. Hospitals that want a pre-bill AI pass over finished charts to catch missed revenue and denial risk before the claim goes out.
Acute-care focused and enterprise-only, so it does not serve ambulatory groups or individual clinicians. Its weakest dimension scores are 3/10 on access & transparency for AI CDI and utilization review, 8/10 on traceability & auditability for AI CDI and utilization review and 8/10 on ehr & deployment for AI CDI and utilization review.
Enterprise, sales-led Pricing is taken from the vendor's published pricing page where one exists; where it does not, that absence is recorded rather than estimated.
EvidenceMD, Regard, Solventum 360 Encompass and Waystar / Iodine Software are scored against SmarterDx on at least one shared rubric. Against EvidenceMD for AI CDI and utilization review: 37–42. Against Regard for AI CDI and utilization review: 37–34. Against Solventum 360 Encompass for AI CDI and utilization review: 37–36. Against Waystar / Iodine Software for AI CDI and utilization review: 37–38.
